ESMO 2023 | LITESPARK-005: Belzutifan versus everolimus in ccRCC

Laurence Albiges, MD, PhD, Gustave Roussy Institute, Villejuif, France, reports on results of the Phase III LITESPARK-005 (NCT04195750) trial which compares belzutifan to everolimus in patients with pretreated advanced clear cell renal cell carcinoma (ccRCC). Primary endpoints were progression-free survival (PFS) as per RECIST 1.1 and overall survival (OS). The data showed that more patients remained progression-free at 12 months with belzutifan versus everolimus (PFS rates 33.7% and 17.6% respectively). There was no statistically significant difference in OS evident between the two arms, but belzutifan was associated with a statistically significant improvement in objective response rate (ORR) compared to everolimus. No new safety signals were observed. This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.